title: Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica.
abstract: Human papillomavirus (HPV) seroprevalence and determinants of seropositivity were assessed in a 10049-woman population-based cohort in Guanacaste, Costa Rica. Serologic responses based on VLP-based ELISA were obtained from the plasma collected at study enrollment in 1993/1994 for HPV-16 (n=9949), HPV-18 (n=9928), HPV-31 (n=9932), and HPV-45 (n=3019). Seropositivity was defined as five standard deviations above the mean optical density obtained for studied virgins (n=573). HPV-16, -18, -31, and -45 seroprevalence was 15, 15, 16, and 11%, respectively. Of women DNA-positive for HPV-16, -18, -31, or -45, seropositivity was 45, 34, 51, and 28%, respectively. Peak HPV seroprevalence occurred a decade after DNA prevalence; lifetime number of sexual partners was the key determinant of seropositivity independent of DNA status and age. DNA- and sero-positive women showed the highest risk for concurrent CIN3/cancer, followed by DNA-positive, sero-negative women.
authors.affiliation: National Cancer Institute, Bethesda, MD 20892-7234, USA. wangso@mail.nih.gov
authors.forename: S S
authors.initials: SS
authors.lastname: Wang
authors.forename: M
authors.initials: M
authors.lastname: Schiffman
authors.forename: T S
authors.initials: TS
authors.lastname: Shields
authors.forename: R
authors.initials: R
authors.lastname: Herrero
authors.forename: A
authors.initials: A
authors.lastname: Hildesheim
authors.forename: M C
authors.initials: MC
authors.lastname: Bratti
authors.forename: M E
authors.initials: ME
authors.lastname: Sherman
authors.forename: A C
authors.initials: AC
authors.lastname: Rodriguez
authors.forename: P E
authors.initials: PE
authors.lastname: Castle
authors.forename: J
authors.initials: J
authors.lastname: Morales
authors.forename: M
authors.initials: M
authors.lastname: Alfaro
authors.forename: T
authors.initials: T
authors.lastname: Wright
authors.forename: S
authors.initials: S
authors.lastname: Chen
authors.forename: B
authors.initials: B
authors.lastname: Clayman
authors.forename: R D
authors.initials: RD
authors.lastname: Burk
authors.forename: R P
authors.initials: RP
authors.lastname: Viscidi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood*; D000956:Antigens, Viral / Q000276:immunology; D015331:Cohort Studies; D003364:Costa Rica / Q000453:epidemiology; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D006801:Humans; D008875:Middle Aged; D027383:Papillomaviridae / Q000235:genetics / Q000276:immunology*; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000821:virology; D016133:Polymerase Chain Reaction; D016036:Seroepidemiologic Studies; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology* / Q000821:virology
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D004279:DNA, Viral